Analysis of top Seeking Alpha coverage: Ablynx
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF).
On Monday, Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered euro 28 per share to Ablynx after the latter thwarted earlier offers from Novo. Following Ablynx’s stance, Novo decided to go public with its new and improved offer. Ablynx though has rejected the latest offer as well, noting that it undervalues the company. Interestingly, Ablynx shares were